News

In June 2014, EnGeneIC completed a Phase 1 trial in recurrent glioma in Australia and now plans to submit an IND and commence the U.S. clinical program in

Bruce Burns, Senior Vice President at Windmill, said, "Our pharmacies like the fact that we bring them new innovative products of this caliber." "We have nothing else like

This first step towards identification of new classes of targeted anti-infectious drugs was achieved only 9 months after signature of a discovery collaboration will trigger the payment of

Preliminary data from the Cook/Selexis-sponsored proof-of-concept program has been published in the June issue of BioProcess International in an article titled, "Rapid Development and Scale-Up Through Strategic Partnership:

As part of the option deal, Aurigene will receive an upfront payment from Orion, followed by a licensing fee, milestones and royalties upon exercising the option at the

According to the company, early launch of these products was fueled by the strong feedback from many national retailers in the US. The company has been working with

Ligand’s IRAK4 is a major signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with

As part of the deal, Abbott will acquire Garden Hills, which currently owns more than 80% of Veropharm, for about $395m or $495m, depending on Garden Hills’ share

The company said that BNC375 and related compounds have displayed potent efficacy in animal cognitive impairment models. As part of the deal, Merck will provide funding for all